Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Taiwan University Hospital |
---|---|
Information provided by: | National Taiwan University Hospital |
ClinicalTrials.gov Identifier: | NCT00173394 |
Ovarian cancer is the first in mortality rate of the gynecologic malignancies and the overall 5-year survival rate of ovarian cancer is only 20–30%. Besides, the incidence of ovarian cancer increased in recent years in Taiwan. Ovarian cancer is indeed a disease that should be respected, however, there has only been a little research done focusing on it in Taiwan. Patients with ovarian cancer who have stage I disease (localized to ovaries) after optimal surgical staging do not need any adjuvant therapy. In contrast, patients with disease spreading beyond the ovaries have median survival rates that decrease to < 10% for patients with bulky residual disease after surgery and treated with platinum-based combination chemotherapy. In developing effective therapy for ovarian cancer, there should be a distinction between preventative and therapeutic approaches.
Immunoprevention will be developed for women who are at an increased risk for the development of ovarian cancer.
In contrast, immunotherapy would be used as an adjuvant to surgery or in combination with chemotherapy or other biologics as chemoimmunotherapy or biochemoimmunotherapy. Mesothelin is expressed in some normal epithelial cells and is elevated in certain carcinomas. Mesothelin has been reported to be selectively overexpressed in most of the non-mucinous ovarian carcinomas. In addition, the specific epitopes of mesothelin in the HLA-A2 and A24 haplotype have been identified. It seems that mesothelin has the potential to be a target antigen for the immunotherapy of ovarian cancer. So the investigators would like to provide this proposal to address the development of mesothelin -specific immunologic assays. There are two aims in this project:
Condition |
---|
Ovarian Cancer |
Study Type: | Observational |
Study Design: | Natural History, Cross-Sectional, Defined Population, Retrospective/Prospective Study |
Estimated Enrollment: | 250 |
Study Start Date: | August 2005 |
Estimated Study Completion Date: | December 2008 |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Contact: Chi-An Chen, MD | 886-2-2312-3456 ext 5157 | cachen@ha.mc.ntu.edu.tw |
Taiwan | |
National Taiwan University Hospital | Recruiting |
Taipei, Taiwan | |
Contact: Chi-An Chen, MD 886-2-2312-3456 ext 5157 cachen@ha.mc.ntu.edu.tw |
Principal Investigator: | Chi-An Chen, MD | National Taiwan University Hospital |
Study ID Numbers: | 9461700630 |
Study First Received: | September 12, 2005 |
Last Updated: | December 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00173394 History of Changes |
Health Authority: | Taiwan: Department of Health |
ovarian cancer immunotherapy mesothelin normal volunteer |
Genital Diseases, Female Ovarian Neoplasms Gonadal Disorders Genital Neoplasms, Female Ovarian Cancer |
Endocrine System Diseases Urogenital Neoplasms Endocrinopathy Ovarian Diseases Endocrine Gland Neoplasms |
Genital Diseases, Female Neoplasms Neoplasms by Site Ovarian Neoplasms Gonadal Disorders Genital Neoplasms, Female |
Endocrine System Diseases Urogenital Neoplasms Ovarian Diseases Adnexal Diseases Endocrine Gland Neoplasms |